Yourgene Health PLC Further testing service agreement for MHC
17 May 2021 - 4:00PM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
17 May 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Further testing service agreement for MyHealthChecked plc
Yourgene Genomic Services to support MHC's second Boots
agreement for Day 2 & Day 8 testing
for international arrivals to the UK
Manchester, UK - 17 May 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that its
partner MyHealthChecked plc (AIM:MHC) ("MyHealthChecked") has
signed a second COVID-19 testing services agreement, to support the
supply of the MyHealthChecked(TM) COVID-19 at-home nasal swab kit,
PCR laboratory testing service and logistics for day two and day
eight ("D2/D8") coronavirus testing for international arrivals, to
Boots UK Limited ("Boots"), the health and beauty retailer and
pharmacy group.
Through the service agreement, a proportion of the
MyHealthChecked(TM) COVID-19 tests will be processed by Yourgene
Genomic Services ("YGS") at the Company's Citylabs 1.0 laboratory
in Manchester which are well equipped to deal with the anticipated
increased demand for D2/D8 testing. In addition, samples processed
at MyHealthChecked's own laboratories will use Yourgene's Clarigene
(R) SARS CoV-2 PCR CE-IVD test kit. MyHealthChecked is currently
the only at-home testing kit provider within Boots for General
Testing and Fit-to-Fly services, as launched on 7 April 2021, and
is now accompanied by D2/D8 tests that will be available
to purchase online, via www.boots.com across the UK, from 17 May 2021.
Lyn Rees, CEO of Yourgene Health and Non-Executive Director of
MyHealthChecked, commented: "This further contract with Boots is
another significant milestone for MyHealthChecked and Yourgene is
pleased to continue supporting their COVID-19 testing service and
product supply to their laboratory. With the introduction of the
new traffic light system in the UK for global travel, we will see
an increased demand for D2/D8 testing, as travel resumes, and this
further contract for MyHealthChecked is a testament to the quality
of the service provided."
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Tel: +44 (0)20 7496 3000
N+1 Singer (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAAFMRTMTJBBFB
(END) Dow Jones Newswires
May 17, 2021 02:00 ET (06:00 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Sep 2023 to Sep 2024